Search Results
Oct 27, 2025, 13:00 ET Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea
Chang JL, Goldberg AN, Alt JA, et al. International consensus statement on obstructive sleep apnea. Int Forum Allergy Rhinol. 2023;13(7):1061-1482.
More news about: Eli Lilly and Company
Oct 22, 2025, 09:00 ET First Community Corporation Announces Third Quarter Results and Cash Dividend
Int bearing deposits in other banks
More news about: First Community Corporation
Oct 20, 2025, 20:00 ET 第10回中国国際著作権博覧会及び2025国際著作権フォーラムが青島で開催
青島（中国）、2025年10月21日 /PRNewswire/ -- Chengda Int. Mediaより： 10月16日、中国国家著作権局、世界知的所有権機関が主催し、山東省著作権局、青島市人民政府が開催した第10回中国国際著作権博覧会及び2025国際著作権フォーラムが青島で開幕した。
More news about: CHENGDA(QINGDAO) INTERNATIONAL MEDIA CO.,LTD.
Oct 20, 2025, 17:31 ET Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsight
molecular profiling and targeted therapies are attracting investment and clinical development. Furthermore, the launch of emerging therapies such as INT230-6, Alrizomadlin (APG-115), BOXR1030, BTX-A51, CEB-01, Letetresgene Autoleucel, and others will propel the market.
More news about: DelveInsight Business Research, LLP
Oct 20, 2025, 06:30 ET IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
similar decrease in radiation to the tumor apex is associated with improved visual outcomes (Perez et al, Int J Radiat Oncol Biol Phys. 2014; Kheir et al, Adv Radiat Oncol. 2022; Saconn et al, Int J Radiat Oncol Biol Phys. 2010; Puusaari et al, Invest Ophthalmol Vis Sci. 2004).64.9% (24/37) of
More news about: IDEAYA Biosciences, Inc.
Oct 19, 2025, 03:24 ET 從身心健康到學業表現--為何香港家長要約束子女使用社交媒體及電子產品？
Use of Social Media in Children and Adolescents: Scoping Review on the Potential Risks. Int J Environ Res Public Health. 2022;19(16):9960. [4] Amez S, Baert S. Smartphone use and academic performance. Int J Educ Res 2020;103:101618. [5] Bottger T, Zierer K. To Ban or Not to Ban? A rapid
More news about: Look Up Hong Kong
Oct 16, 2025, 14:30 ET Nabsys Presents Novel Disease Insights and Advantages in Structural Variant Detection using OhmX™ Platform at American Society of Human Genetics (ASHG) 2025 Annual Meeting
patients with interstitial cystitis/bladder pain syndrome (IC/BPS) have psychiatric comorbidities and uncovers novel proteomic and genetic insights int o IC/BPS EGM offers streamlined analysis and
More news about: Nabsys
Oct 15, 2025, 10:50 ET Alcoholic Hepatitis Treatment Market to Reach $772.7 Million by 2027 in the short term and $1,064.98 Million by 2034 Globally, at 4.7% CAGR: Allied Market Research
institutions. For instance, in November 2022, Intercept Pharmaceuticals, Inc. announced plans to focus development of its next-generation FXR agonist, INT-787, in severe alcohol-associated hepatitis (sAH). Alcohol-related liver disease is currently the leading indication for liver transplant listing in the
More news about: Allied Market Research
Oct 15, 2025, 07:30 ET Endo Announces Peyronie's Disease Presentation at the North Central Section of the American Urological Association
law. References Hellstrom WJ. Int J Impot Res. 2003;15(Suppl 5):S91–S92. Stuntz M, Perlaky A, des Vignes F, et al. PLoS One. 2016;11(2):e0150157.
More news about: Endo USA, Inc.
Oct 14, 2025, 12:29 ET Smart Snacking Part of a Healthy Diet
Effects of chronic peanut consumption on energy balance and hedonics. Int J Obes Relet Metab Disord. 2002 Aug;26(8):1129-37. doi: 10.1038/sj.ijo.0802050. PMID: 12119580. Zhang D, Dai C, Zhou L, et
More news about: The Peanut Institute
Oct 14, 2025, 03:30 ET First patient treated with Leqembi® (lecanemab) in the Nordics
[5] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. [6] Morris
More news about: BioArctic
Oct 10, 2025, 07:30 ET Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
https://www.nami.org/early-onset-schizophrenia/understanding-schizophrenia/ Alphs L, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable therapy. Int Clin Psychopharmacol. 2016;31(4)202-209. doi:10.1097/YIC.0000000000000125 © Johnson & Johnson 2025.
More news about: Johnson & Johnson
Oct 09, 2025, 16:15 ET Endo Announces Nine New and Modified Presentations at the Sexual Medicine Society of North America (SMSNA) Annual Meeting
law. References Hellstrom WJ. Int J Impot Res. 2003;15(Suppl 5):S91–S92. Stuntz M, Perlaky A, des Vignes F, et al. PLoS One. 2016;11(2):e0150157.
More news about: Endo USA, Inc.
Oct 09, 2025, 06:29 ET Conçu pour les extrêmes. Fait pour l'éternité. Mammut Eiger Extreme Nordwand 6.0
Mammut : https://www.mammut.com/int/en/featured/5810/featured-eiger-extreme À propos de Mammut Fondée
More news about: Mammut Sports Group AG
Oct 09, 2025, 06:23 ET Diseñado para condiciones extremas. Hecho para la eternidad. Mammut Eiger Extreme Nordwand 6.0
Mammut.: https://www.mammut.com/int/en/featured/5810/featured-eiger-extreme Acerca de Mammut Fundada en 1862, Mammut es
More news about: Mammut Sports Group AG
Oct 08, 2025, 13:44 ET Entwickelt für die Extreme. Gemacht für die Ewigkeit: Mammut Eiger Extreme Nordwand 6.0.
Mammut: https://www.mammut.com/int/en/featured/5810/featured-eiger-extreme Über Mammut Mammut ist ein
More news about: Mammut Sports Group AG
Oct 08, 2025, 13:30 ET Engineered for the Extremes. Made for Eternity. Mammut Eiger Extreme Nordwand 6.0
Mammut: https://www.mammut.com/int/en/featured/5810/featured-eiger-extreme About Mammut Founded in 1862,
More news about: Mammut Sports Group AG
Oct 08, 2025, 01:30 ET Leadership changes at Landmark Group: Shital Mehta, Managing Director - Lifestyle International Pvt. Ltd., takes on a Broader Mandate; Sumit Chandna Appointed as CEO, Max Fashion India
retailer. https://www.landmarkgroup.com/int/en/home Photo:
More news about: Landmark Group India
Oct 07, 2025, 05:30 ET Cardinal Health launches a new all-in-one solution for deep vein thrombosis and pulmonary embolism prevention
pneumatic compression systems. A hemodynamic study. Int Angiol. 2005;24(4):330-5. 2. Griffin M, et al. Comparison of three intermittent pneumatic compression systems in patients with varicose veins: A haemodynamic study. Int Angiol. 2007 Jun;26:158-64.
More news about: Cardinal Health
Oct 06, 2025, 18:05 ET Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
[5] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. [6] Morris
More news about: BioArctic
Oct 06, 2025, 18:02 ET Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
[5] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. [6] Morris
More news about: BioArctic
Oct 06, 2025, 16:30 ET Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
doi:10.1038/s41467-021-23507-z Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. Morris JC. Neurology. 1993;43(11):2412-4.
More news about: Eisai Inc.
Oct 02, 2025, 09:00 ET LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
Rao SV, O'Donoghue ML, Ruel M, et al. Circulation. 2025;151(13):e771-e862. Vinci P, Di Girolamo FG, Panizon E, et al. Int J Environ Res Public Health. 2023;20(18):6721. Published 2023 Sep 6. doi:10.3390/ijerph2018672. Stein EA, Wasserman SM, Dias
More news about: Amgen
Oct 02, 2025, 03:23 ET Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025
Disorders 2025. Burns MR, McFarland NR. Neurotherapeutics. 2020;17:1582–1602. Mészáros L, et al. Int J Mol Sci. 2020;21:2775. Kidwell KM, et al. Orphanet J Rare Dis. 2022 May 7;17(1):186 Garczarek
More news about: H. Lundbeck A/S
Oct 02, 2025, 03:20 ET Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025
Disorders 2025. Burns MR, McFarland NR. Neurotherapeutics. 2020;17:1582–1602. Mészáros L, et al. Int J Mol Sci. 2020;21:2775. Kidwell KM, et al. Orphanet J Rare Dis. 2022 May 7;17(1):186 Garczarek
More news about: H. Lundbeck A/S